Every 8-K that Inhibrx Biosciences, Inc. (INBX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow INBX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full INBX filings page.
Inhibrx Biosciences, Inc. (INBX) reported positive randomized Phase 2 data from its HexAgon study of INBRX-106 plus pembrolizumab in first-line PD-L1–positive metastatic or unresectable recurrent HNSCC. Among 63 evaluable patients at an August 19, 2026 cutoff, the combination achieved a confirmed objective response rate of 48.3% versus 26.5% for pembrolizumab alone, including complete responses in 13.8% of combination patients and none on monotherapy.
Median progression-free survival was 9.6 months for the combination versus 4.9 months for pembrolizumab, with six‑month PFS rates of 72.4% and 42.8%, respectively. In HPV+ patients, cORR was 80.0% vs 33.3%, with 30.0% complete responses and 90.0% six‑month PFS for the combination versus 0% complete responses and 33.0% six‑month PFS for pembrolizumab. The combination’s safety profile was generally manageable, with mostly low‑grade rash, fatigue, and diarrhea.
Based on these results, Inhibrx plans to expand the randomized Phase 2 portion of HexAgon by approximately 50 additional HPV+ OPSCC patients (CPS ≥ 1) to support a potential accelerated regulatory pathway, then initiate a Phase 3 confirmatory trial after alignment with the FDA. INBRX-106 is also being studied in a Phase 1/2 perioperative NSCLC trial with an initial data readout targeted by mid‑2027 and is being positioned for broader use in highly immunogenic tumors and in combination with therapeutic cancer vaccines.
Inhibrx Biosciences, Inc. reported second quarter 2026 results with a net loss of $36.7 million, or $2.34 per share, compared to a net loss of $28.7 million a year earlier. The company reported no revenue in the quarter versus $1.3 million in Q2 2025.
Research and development expenses were $23.9 million and general and administrative expenses were $8.3 million, both higher than the prior-year period, while total other expense rose to $4.5 million mainly from increased interest on debt. As of June 30, 2026, cash and cash equivalents were $133.3 million; including proceeds from a July loan amendment, cash reached $219.5 million as of August 6, 2026. A second amendment to the Oxford Finance loan provides up to $325.0 million in additional gross proceeds, of which $100.0 million was funded. The FDA accepted the biologics license application for ozekibart in conventional chondrosarcoma with a PDUFA goal date of April 14, 2027, and the company plans further clinical and regulatory milestones for ozekibart and INBRX-106.
Inhibrx Biosciences, Inc. entered into a Second Amendment to its Loan and Security Agreement with Oxford Finance, expanding its Credit Facility to an aggregate principal amount of $500.0 million.
The amendment adds an additional tranche of up to $325.0 million, including a $100.0 million Term C Loan funded at signing and up to $225.0 million of Term D Loans that may be drawn in increments of $50.0 million or more at the Lenders’ sole discretion upon the company’s request. Prior to the amendment, Inhibrx had drawn $175.0 million under the facility.
In connection with the Term C funding, Inhibrx issued the Lenders warrants to purchase 21,457 common shares at an exercise price of $93.21 per share, stated as equal to 2.0% of the Term C Loan value, exercisable immediately for 10 years, with anti-dilution adjustments. Additional warrants sized at 2.0% of any Term D funding will be issued on similar pricing mechanics. Inhibrx also pledged all of its equity in Poplar Therapeutics, Inc. as collateral. The warrants were issued in transactions exempt from registration under Section 4(a)(2) of the Securities Act and/or Rule 506 of Regulation D.
Inhibrx Biosciences reported that the U.S. FDA has accepted for filing its Biologics License Application for ozekibart (INBRX-109) to treat patients with unresectable or metastatic conventional chondrosarcoma and has set a PDUFA goal date of April 14, 2027.
The BLA is backed by the registrational ChonDRAgon study, where ozekibart cut the risk of disease progression or death by 52% versus placebo (hazard ratio 0.479) and more than doubled median progression-free survival to 5.52 months vs 2.66 months. Disease control rate and pain and function measures also favored ozekibart.
If approved, ozekibart would be Inhibrx’s first commercial product and the first FDA‑approved systemic therapy for this cancer. The drug showed a generally manageable safety profile, with hepatotoxicity mitigated through patient selection and close monitoring.
Inhibrx Biosciences, Inc. reported results from its 2026 Annual Meeting of Stockholders held online on June 3, 2026. A quorum of 11,541,232 shares was present, representing about 79% of the 14,607,286 common shares entitled to vote as of April 7, 2026.
Stockholders elected Class II directors Douglas G. Forsyth and Kimberly Manhard to serve until the 2029 Annual Meeting and until their successors are duly elected and qualified, or earlier death, resignation, or removal. Forsyth received 7,608,469 votes for and 1,463,474 withheld, with 2,469,289 broker non-votes. Manhard received 9,035,097 votes for and 36,846 withheld, with 2,469,289 broker non-votes.
Stockholders also ratified the appointment of BDO USA, P.C. as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 11,510,478 votes for, 30,347 against, and 407 abstentions.
Inhibrx Biosciences, Inc. reported first quarter 2026 results, showing a narrower net loss and a stronger cash position alongside higher debt and a stockholders’ deficit. Net loss was $33.4 million, or $2.15 per share, compared to $43.3 million, or $2.80 per share, in the first quarter of 2025.
Research and development expenses fell to $25.2 million, and general and administrative costs were broadly stable at $5.7 million. Cash and cash equivalents rose to $161.7 million as of March 31, 2026, supported by $75.0 million of additional loan proceeds, which increased long-term debt to $175.0 million and resulted in a stockholders’ deficit of $21.0 million.
Clinically, the company highlighted updated interim data for INBRX-106 in a randomized Phase 2 HNSCC trial and for ozekibart (INBRX-109) in colorectal cancer. It submitted a Biologics License Application for ozekibart in conventional chondrosarcoma and plans key FDA interactions in the second half of 2026.
Inhibrx Biosciences reported encouraging interim Phase 2 data for INBRX-106 in first-line head and neck squamous cell carcinoma with high PD-L1 expression. In the evaluable population, INBRX-106 plus pembrolizumab achieved a confirmed objective response rate of 44.0% (11 of 25 patients) versus 21.4% (6 of 28) with pembrolizumab alone, a 22.6% absolute improvement, including three complete responses in the combination arm and none in the control arm.
Pharmacodynamic analyses showed up to a 15-fold increase in CD8+ and CD4+ T‑cell proliferation and up to a four-fold increase in activation with the combination, compared with up to 2.5-fold and 1.5-fold increases on pembrolizumab alone. The safety profile of INBRX-106 plus pembrolizumab was generally manageable, with mostly low‑grade rash, diarrhea, fatigue and infusion reactions and no treatment-related deaths.
The company plans to start the Phase 3 portion of the HexAgon study in third-quarter 2026 and expects progression‑free survival data from Phase 2 in fourth-quarter 2026. Inhibrx also outlines expansion plans for INBRX-106 into perioperative and front‑line metastatic non‑small cell lung cancer and other checkpoint‑inhibitor‑sensitive tumors, estimating a potential addressable market of about $50 billion if the drug ultimately extends across major PD‑1/PD‑L1 indications.
Inhibrx Biosciences, Inc. reported updated interim results from its Phase 1/2 trial of ozekibart (INBRX-109) plus FOLFIRI in heavily pretreated colorectal cancer. Among 45 evaluable patients, objective response rate was 20% per RECIST v1.1, versus historical standards of care with 1–6% response rates, and nearly half of responses lasted more than six months.
Median progression-free survival was 5.5 months, with 42% of patients progression-free at six months and an overall disease control rate of 87%. Safety remained manageable, with mostly Grade 1–2 diarrhea, fatigue and nausea and no significant liver toxicity despite 68% of patients having baseline liver metastases.
Inhibrx plans to meet the FDA in the second half of 2026 about a first-line registrational colorectal cancer trial and possible accelerated pathways in fourth-line colorectal cancer and refractory Ewing sarcoma. The company also submitted a BLA for ozekibart in conventional chondrosarcoma in April 2026.
Inhibrx Biosciences, Inc. reported fourth quarter and full-year 2025 results and outlined key 2026 clinical milestones. The company is now focused on two clinical programs, ozekibart (INBRX-109) and INBRX-106, following the prior sale of INBRX-101 and spin-off from its former parent.
For 2025, Inhibrx recorded a net loss of $140.1 million, or $9.04 per share, compared with net income of $1.7 billion in 2024, which had included a large one-time gain from the 101 Transaction. Research and development expenses fell to $113.0 million from $203.7 million, while general and administrative expenses declined to $23.3 million from $127.9 million as transaction- and litigation-related costs rolled off.
As of December 31, 2025, cash and cash equivalents were $124.2 million. On March 18, 2026, the company amended its loan agreement with Oxford Finance and received gross proceeds of $75.0 million. Inhibrx expects to submit a BLA for ozekibart in early Q2 2026 and to report multiple ozekibart and INBRX-106 data readouts through 2026.
Inhibrx Biosciences, Inc. furnished an updated investor presentation outlining its oncology pipeline, recent clinical results and financial position. The company reported key metrics as of September 30, 2025, including $153 cash and cash equivalents, 14 common stock outstanding and 19 fully diluted outstanding.
The presentation highlights ozekibart (INBRX-109) registrational trial data in chondrosarcoma, where median progression-free survival reached 5.52 months versus 2.66 months for placebo, with a hazard ratio of 0.479 and P<0.0001. Disease control rate was 54% versus 27.5%.
Early phase 1/2 data for ozekibart in late-line colorectal cancer showed a 92% disease control rate and 23% objective response rate in combination with FOLFIRI, while in Ewing sarcoma, ozekibart plus irinotecan/temozolomide achieved a 92% disease control rate and 64% objective response rate. The presentation also details INBRX-106, a hexavalent OX40 agonist being advanced into a seamless phase 2/3 trial in first-line head and neck squamous cell carcinoma with pembrolizumab.
Inhibrx Biosciences, Inc. reported clinical development updates for its immuno‑oncology programs INBRX‑106 and ozekibart. For INBRX‑106, it has enrolled 46 of 60 patients in the randomized Phase 2 portion of a Phase 2/3 trial in combination with Keytruda as a first‑line treatment for unresectable or metastatic head and neck squamous cell carcinoma, with completion of Phase 2 enrollment expected in the first quarter of 2026. A separate Phase 1/2 cohort of 34 patients with checkpoint inhibitor refractory or relapsed non‑small cell lung cancer in combination with Keytruda has completed enrollment.
Current datasets for both head and neck cancer and lung cancer are not yet mature enough to draw conclusions, and Inhibrx expects data in the second half of 2026 to assess the viability of INBRX‑106 in combination with Keytruda. For ozekibart, Inhibrx has completed enrollment of 44 patients in a Phase 1/2 expansion cohort in advanced colorectal cancer, with progression‑free survival data expected to mature in the second quarter of 2026, and it aims to complete enrollment in an Ewing sarcoma trial in the second quarter of 2026 and then discuss a potential accelerated approval pathway with the FDA in the second half of 2026 if current response trends continue.
Inhibrx Biosciences furnished an 8-K to announce it issued a press release with financial results for the three and nine months ended September 30, 2025. The press release is provided as Exhibit 99.1.
The company states the information under Item 2.02, including Exhibit 99.1, is being furnished and not deemed filed under the Exchange Act, and will not carry Section 18 liability or be incorporated by reference unless expressly specified.
The filing also includes Exhibit 104, the cover page interactive data file embedded in Inline XBRL.
Inhibrx Biosciences (INBX) reported positive topline results from its registrational ChonDRAgon study (n=206) of ozekibart (INBRX-109) in advanced or metastatic, unresectable chondrosarcoma. The trial met its primary endpoint, showing a 52% reduction in risk of progression or death versus placebo (HR 0.479; P<0.0001) and more than doubling median progression-free survival to 5.52 months vs 2.66 months. Disease control rate was 54% vs 27.5%, with consistent benefit across IDH subgroups.
Safety was generally manageable; common events included fatigue, constipation, and nausea. Hepatotoxicity risk was addressed via exclusion of severe hepatic impairment and early-cycle monitoring; treatment-related hepatic adverse events occurred in 11.8% vs 4.5% on placebo.
In expansion cohorts, ozekibart plus FOLFIRI in late-line colorectal cancer showed 23% ORR and 92% disease control (26 evaluable). In refractory Ewing sarcoma with IRI/TMZ, ORR was 64% and disease control 92% (25 evaluable). Inhibrx plans a BLA submission in Q2 2026 and will present detailed data on November 14, 2025 at CTOS.
Inhibrx Biosciences, Inc. furnished a press release announcing its financial results for the three and six months ended June 30, 2025. The press release is furnished as Exhibit 99.1 to this Current Report and an interactive XBRL cover page is included as Exhibit 104.
The company states the information in Item 2.02, including Exhibit 99.1, is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act, so it is subject to different legal treatment than filed disclosures. The report confirms Inhibrx's Nasdaq listing under the ticker INBX and indicates the registrant is an emerging growth company.